Table 1.
Patient characteristics
| Variable | Total | Adjuvant chemotherapya |
P-value | |
|---|---|---|---|---|
| No | Yes | |||
| Patient | 96 (100) | 50 (52.1) | 46 (47.9) | |
| Age (yr) | 77.2 ± 4.9 | 78.9 ± 5.4 | 75.4 ± 3.4 | 0.001* |
| Sex | 0.213 | |||
| Female | 38 (39.6) | 23 (46.0) | 15 (32.6) | |
| Male | 58 (60.4) | 27 (54.0) | 31 (67.4) | |
| Body mass index (kg/m2) | 23.0 ± 3.1 | 22.9 ± 3.3 | 23.2 ± 2.8 | 0.556 |
| Charlson comorbidity index | 0.024* | |||
| 4 | 55 (57.3) | 23 (46.0) | 32 (69.6) | |
| 5–6 | 41 (42.7) | 27 (54.0) | 14 (30.4) | |
| ASA PS classification | 0.835 | |||
| II | 58 (60.4) | 31 (62.0) | 27 (58.7) | |
| III | 38 (39.6) | 19 (38.0) | 19 (41.3) | |
| Pathologic grading | 0.369 | |||
| Well differentiated | 4 (4.2) | 3 (6.0) | 1 (2.2) | |
| Moderately differentiated | 79 (82.3) | 38 (76.0) | 41 (89.1) | |
| Poorly differentiated | 8 (8.3) | 6 (12.0) | 2 (4.3) | |
| Mucinous | 5 (5.2) | 3 (6.0) | 2 (4.3) | |
| pT stage | 0.331 | |||
| pT3 | 74 (77.1) | 41 (82.0) | 33 (71.7) | |
| pT4 | 22 (22.9) | 9 (18.0) | 13 (28.3) | |
| Tumor location | > 0.999 | |||
| Right | 41 (42.7) | 21 (42.0) | 20 (43.5) | |
| Left | 55 (57.3) | 29 (58.0) | 26 (56.5) | |
| Margin < 5 mm | 0.557 | |||
| No | 83 (86.5) | 42 (84.0) | 41 (89.1) | |
| Yes | 13 (13.5) | 8 (16.0) | 5 (10.9) | |
| No. of lymph nodes retrieved | 0.543 | |||
| < 12 | 84 (87.5) | 45 (90.0) | 39 (84.8) | |
| ≥ 12 | 12 (12.5) | 5 (10.0) | 7 (15.2) | |
| Lymphatic invasion | 0.822 | |||
| No | 26 (27.1) | 13 (26.0) | 13 (28.3) | |
| Yes | 70 (72.9) | 37 (74.0) | 33 (71.7) | |
| Venous invasion | 0.107 | |||
| No | 72 (75.0) | 41 (82.0) | 31 (67.4) | |
| Yes | 24 (25.0) | 9 (18.0) | 15 (32.6) | |
| Perineural invasion | 0.528 | |||
| No | 85 (88.5) | 43 (86.0) | 42 (91.3) | |
| Yes | 11 (11.5) | 7 (14.0) | 4 (8.7) | |
| Obstruction | 0.058 | |||
| No | 72 (75.0) | 42 (84.0) | 30 (65.2) | |
| Yes | 24 (25.0) | 8 (16.0) | 16 (34.8) | |
| Perforation | 0.606 | |||
| No | 93 (96.9) | 49 (98.0) | 44 (95.7) | |
| Yes | 3 (3.1) | 1 (2.0) | 2 (4.3) | |
| Preoperative serum CEA level (ng/mL) | 12.7 ± 58.1 | 7.8 ± 21.6 | 17.5 ± 79.5 | 0.858 |
| No. of adverse features | 0.181 | |||
| 1–2 | 69 (71.9) | 39 (78.0) | 30 (65.2) | |
| 3–5 | 27 (28.1) | 11 (22.0) | 16 (34.8) | |
Values are presented as number (%) or mean±standard deviation.
ASA, American Society of Anesthesiologists; PS, physical status; pT stage, pathologic T stage; CEA, carcinoembryonic antigen.
a
Defined as completion of more than 80% of the planned adjuvant chemotherapy cycle.
*
P<0.05.